George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
April 10, 2026
Our clinical program for our lead candidate #visugromab continues to advance. We have dosed the first patient in our Phase 2b GDFATHER-HCC-01 trial, evaluating visugromab in combination with chemoimmunotherapy as a second-line treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have progressed following first line anti-PD-(L)1 based therapy.
Visugromab is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15), an immunosuppressive cytokine that can promote immune evasion and resistance to anti-PD-(L)1 therapies and is implicated in #CancerCachexia.
Through this trial, we aim to advance a combination strategy that may help restore anti-tumor responses in a setting where treatment options remain limited.
